Democratic People's Republic of Korea
Tuberculosis profile
Population  2013 25 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 6.7 (3–11) 27 (12–46)
Mortality (HIV+TB only) 0.018 (<0.01–0.03) 0.07 (0.04–0.12)
Prevalence  (includes HIV+TB) 130 (36–290) 536 (146–1 175)
Incidence  (includes HIV+TB) 110 (100–110) 429 (401–456)
Incidence (HIV+TB only) 0.12 (0.056–0.13) 0.49 (0.22–0.53)
Case detection, all forms (%) 91 (86–98)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.8–2.7) 16 (12–20)
MDR-TB cases among notified pulmonary
TB cases
1 600 (1 300–2 000) 2 300 (1 800–2 900)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 33 595   7 074
Pulmonary, clinically diagnosed 38 838   0
Extrapulmonary 18 158   0
       
Total new and relapse 97 665    
Previously treated, excluding relapses 7 247    
Total cases notified 104 912    
Among 90 591 new cases:
5 239 (6%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 187 (1%) 187
Laboratory-confirmed RR-/MDR-TB cases     244
Patients started on MDR-TB treatment     170
TB/HIV 2013 Number (%)
TB patients with known HIV status 0 (0)
HIV-positive TB patients 0  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 92
Previously treated cases, excluding relapse, registered in 2012 84
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 17
% Funded domestically 30%
% Funded internationally 63%
% Unfunded 6%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-27 Data: www.who.int/tb/data